Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23163258 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL19947656 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL862327 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL14511330 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL915393 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL29025599 | 0.97 | KMT2A (0.59) | MEN1KMT2AMAPTATMHSD17B10 | |
| SCHEMBL65035 | 0.97 | — | — | |
| SCHEMBL19617353 | 0.97 | — | — | |
| SCHEMBL25299343 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL8578344 | 0.95 | KMT2A (0.56) | MEN1KMT2AMAPTATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |
| US-20240034825-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION | 2024-02-01 | — | — | US | disclosed |
| WO-2023168218-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-116368159-A | Process and catalyst for hydrogen-mediated anionic polymerization of conjugated dienes and liquid polymers thereof | 雅宝公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-115201485-A | Methods of measuring KRAS protein inhibition | 百济神州(北京)生物科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| CN-105121436-B | New pyridine derivate | 豪夫迈·罗氏有限公司 | 2018-07-27 | — | — | CN | disclosed |
| EP-2978755-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-2978755-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | MEN1 130/4885KMT2A 1301/4885MAPT 2045/4885 |
| US-10308659-B2 | Pyridine derivatives | NDUFS6, NDUFS4, NDUFS8 | MEN1 1163/4885KMT2A 2224/4885MAPT 1696/4885 |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | MEN1 2680/4885KMT2A 2712/4885MAPT 1920/4885 |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | MEN1 2680/4885KMT2A 2712/4885MAPT 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.